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Nutritional support and prophylaxis of
azithromycin for pregnant women to
improve birth outcomes in peri-urban
slums of Karachi, Pakistan—a protocol of
multi-arm assessor-blinded randomized
controlled trial (Mumta PW trial)
Ameer Muhammad1, Zoha Zahid Fazal2, Benazir Baloch3, Imran Nisar3, Fyezah Jehan3 and Yasir Shafiq1*

Abstract
Background: Maternal undernutrition is critical in the etiology of poor perinatal outcomes and accounts for 20% of
small-for-gestational-age (SGA) births. High levels of food insecurity, antenatal undernourishment, and childhood
undernutrition necessitate the supplementation of fortified balanced energy protein (BEP) during pregnancy in lowincome settings especially with scarce literature available in this subject. Hence, this paper extensively covers the
protocol of such a trial conducted in an urban slum of Karachi, Pakistan.
Methods: The trial is community-based, open-labelled, four-arm, and randomized controlled that will include
parallel group assignments with a 1:1:1:1 allocation ratio in low-income squatter settlements in urban Karachi,
Pakistan. All pregnant women (PW), if identified between > 8 and < 19 weeks of gestation based on ultrasound, will
be offered routine antenatal care (ANC) counseling and voluntary participation in the trial after written informed
consent. A total number of 1836 PW will be enrolled with informed consent and randomly allocated to one of the
four arms receiving: (1) ANC counseling only (control group), (2) ANC counseling plus BEP supplement (intervention
arm 1), (3) ANC counseling plus BEP supplement plus 2 doses azithromycin (intervention arm 2), or (4) ANC
counseling plus BEP supplement plus daily single dose of nicotinamide and choline (intervention arm 3).
Trial registration: ClinicalTrials.gov NCT04012177. Registered on July 9, 2019.

Background
Suboptimal nutrition during pregnancy may compromise
maternal health, birth outcomes, and offspring development [1, 2]. Undernourishment in utero can stress the
developing fetus and adversely reprogram its evolving
phenotype [3]. Growth-restricted fetuses are thereafter
* Correspondence: Yasir.shafiq@vitalpakistantrust.org
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Present address: VITAL Pakistan Trust, Karachi, Pakistan
Full list of author information is available at the end of the article

predisposed to several perinatal health risks [4] including
intrauterine growth retardation (IUGR), preterm delivery
[5], low birth weight (LBW), immunocompromised status, childhood stunting, and neurocognitive deficits in
addition to fetal, maternal, and infant mortality [6–8].
Hence, maternal undernutrition poses a significant global health burden [9], accounting for 7% morbidity [10]
plus 70% neonatal [11] and 20% maternal [10] mortality
rates worldwide. This situation is even more dismal for
resource-constrained and food-insecure countries like
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Pakistan, where 18% of married women of reproductive
age are nutrient-deficient, and thus 44% of children have
stunted growth [12].
Maternal undernutrition is, in fact, a significant determinant of LBW in developing countries [13]. An indicator to measure LBW is small-for-gestational-age (SGA),
defined as birth weight below the 10th percentile of optimal weight for a given gestational age and sex of a population subset [14]. Of the 23.3 million SGA births
globally [15], around 20% are attributable to maternal
undernutrition during pregnancy [16]. To address this,
the World Health Organization Antenatal Care (WHOANC) guidelines recommend the use of fortified balanced energy protein (BEP) supplements during pregnancy to reduce the risk of stillbirth and SGA birth [17].
Following this recommendation, compositional guidance
for a ready-to-use supplementary food (RUSF) for pregnant women was developed by the Bill and Melinda
Gates Foundation (BMGF) in 2016 [18].
Additionally, the use of prophylactic antibiotics and
micronutrients along with BEP supplements have shown
to improve perinatal outcomes when used solitarily in
various maternal nutritional interventions across low- and
middle-income populations [19–21]. For instance, the incidence of preterm delivery and LBW is noted to reduce
when two azithromycin doses are administered as a preventive measure for maternal reproductive tract infections
[22]. Similarly, a higher maternal choline intake, an essential micronutrient for neurogenesis [23], reportedly improves fetal neurocognitive development [24]. Lastly,
dietary supplementation with vitamin B3 or nicotinamide
may protect against retarded linear growth in children, as
suggested by a recent cohort study [25].
Although substantial data on solitary administration of
macro- and micro-nutritional supplements and antimicrobial prophylaxis during pregnancy exists, there is a
need for further exploration of the efficacy and synergistic role of these micro- and macro-ingredients on pregnant women (PW) when administered concomitantly. In
the context of Pakistan, recent experience with such
ready-to-use supplements has been limited. Also, in
many cases, these products’ acceptability, efficacy, and
effectiveness have not been adequately studied to understand the circumstantial needs. Our study aims to fulfill
this lacuna by evaluating and comparing the efficacy of
fortified, balanced energy protein (BEP) supplements in
malnourished PW from impoverished settings. This will
be coupled with or without two prophylactic doses of
oral azithromycin and micronutrient fortification with
nicotinamide and choline.
Objectives

The primary objective is to compare the efficacy of fortified, balanced energy protein (BEP) supplements in
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pregnant women (intervention arm 1) administered solitarily, or in combination with two prophylactic dose of
oral azithromycin at weeks 20 and 28 of pregnancy
(intervention arm 2), or in combination with daily oral
supplements of nicotinamide and choline (intervention
arm 3) with that of standard antenatal care (ANC) versus nutritional counseling alone (control arm) in improving the birth weight assessed less than 72 h of birth.
The secondary objective is to compare the impact of the
interventions on birth length and other anthropometric
measurements of the newborn and mother at birth. Further, blood and stool biomarkers of the subjects will be
assessed during pregnancy while cord blood, breast milk,
and colostrum will be collected at birth. During extended follow-ups from 0 to 11 months, mother-infant
dyad will be assessed for anthropometry, and blood and
stool specimens will be collected periodically from the
sub-sample of the dyad.

Methods
Trial design

This is a multi-arm community-based randomized controlled, open-label, assessor-blinded superiority trial with
a treatment allocation ratio of 1:1:1:1. A multi-arm trial
was selected to determine the incremental impact of
BEP to the pregnant woman, along with two doses of
oral azithromycin or oral daily nicotinamide and choline
on birth weight. This protocol has been developed in accordance with the guidelines set forth by Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) [26].
Study setting

The trial will be conducted at Rehri Goth, an impoverished peri-urban coastal slum located along the Arabian
Sea belt in the Malir District of Karachi, Pakistan. This
ancient site comprises of Sindhi and Baloch ethnicities
and a predominant Islamic religion with high illiteracy
rate. With approximately 59,000 residents based on a
2017 census, this site has an annual birth rate of around
1500 per year and a cohort of 22% child-bearing-aged female and 3.6% infant population [27]. There are 25
clinics in the area with only one qualified (MBBS) doctor, one government out-patient health center and no
maternity home. The lady health workers serving the site
belong to Agha Khan Health Services. Major diseases
prevalent are diabetes mellitus, skin disorders, and hepatitis [28]. The main occupation in the village is fishing,
which is seasonal and yields low income due to unfavorable weather conditions and law restrictions. Seasonal
rainfall results in flooding and increases the risk of enteric infections [29]. In the target population, around
27% of pregnant women are malnourished, while about
54% are anemic and approximately 20% of babies are
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born with low birth weight, according to unpublished
data from the VITAL Pakistan Trust (VPT). Thus, Rehri
Goth has been a significant focus of VPT operations in
tandem with the Aga Khan University Hospital (AKUH)
as its partner organization.

Study population and eligibility

Pregnant women between 13 and 49 years of age will be
enrolled if they fulfill the inclusion and exclusion criteria
provided in Table 1. New pregnancies in the catchment
area are usually identified during routine surveillance
rounds and referred to the ANC clinic of VPT. Women
with gestational age between > 8 and < 19 weeks based
on ultrasound will be screened for eligibility by the research trial team onsite. For eligible participants, written
informed consent will be obtained in the local language
before they are enrolled for the trial.

Sample size

The sample size is calculated via permutation and subsequent adjustment for three comparisons between
arms, i.e., intervention arms with control. Improved
perinatal outcomes are hypothesized with the supplement of BEP alone or co-administration of BEP supplement with azithromycin as well as with nicotinamide
and choline. Thus, the sample size estimated per arm is
based on 1-tailed hypothesis testing of birth weight as
the primary outcome, a significance level of 2.5% to account for multiple comparisons, and initial assumption
of dropout proportion of 21% of study participants assumed in the trial. For birth weight (the primary outcome), it is assumed that the mean difference will be at
least 100 g [30]. In order to achieve a test power of 80%
and maintain family-wise error rate (FWER) of 0.05;
Bonferroni method for three comparisons, alpha of
0.017, and an estimated sample size of 370 pregnant
women per arm was attained. A 21% dropout rate was
thereafter considered on account of miscarriages, stillbirths, early neonatal deaths, losses to follow-ups, and
missed birth assessments due to varying on-field challenges owing to the pandemic. Hence, the sample size
was thereafter adjusted to 471 pregnant women in each
arm making up a total of 1884 pregnant women for this
trial.
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Recruitment

Because married women are included in the surveillance
system established by the Department of Pediatrics and
Child Health at the Aga University, VITAL Pakistan
Trust has access to a list of all the pregnant women in
the catchment area. Using that list, all households with
pregnant women will be visited by the research team to
offer standard ANC services. Thereby, during each pregnancy milestone, antenatal and nutritional counseling
will be provided about optimal care-seeking approaches.
At the time of clinical ANC visit for delivery, these
women will be reapproached by the randomization/enrollment team so that their eligibility is assessed for the
trial.
Informed consent procedure

Eligible pregnant women fulfilling the predefined inclusion criteria will be explicitly explained the aims of the
study, procedures and duration of the enrollment. In a
household where decision-makers are either husbands
or other senior family members (not a woman independently), permission from those decision-makers will be
sought to avoid loss to follow-up at a later stage. Adequate time will be given to each participant, i.e., 24–48
h, for discussion with the family members to avoid dropouts and non-compliance. Consent for study participation will be obtained by the research assistant in the
presence of a community health worker. To ensure comprehension of the trial and study procedures, clear verbal
communication in the study participant’s native language will be imparted. Uneducated participants will be
asked to give a thumb impression on the consent form;
literate guardians will be requested to sign the consent
form.
Randomization and allocation concealment

After written informed consent is obtained, randomization
will be performed by the team. Stratified block
randomization with blocks of sizes 4, 8, and 12 will be
used. Sequence generation will be performed by an independent statistician using a random selection method before the beginning of the trial. Self-adhesive, pre-coded
sticky labels with unique identification numbers will be
applied to sealed opaque envelopes containing the coded
randomization identification number and intervention
name to ensure that the randomization process and

Table 1 Inclusion and exclusion criteria
Inclusion

Exclusion

▪
▪
▪
▪
▪
▪

▪ Pregnant women with mid-upper arm circumference
(MUAC) ≥ 30.5 cm
▪ Known food allergies

Gestational age of 8 to 19 weeks confirmed by ultrasound
A resident of the area for at least the last six months.
Willing to spend the whole pregnancy duration after enrollment
Singleton and viable fetus on ultrasound
Not working and available for ANC and follow-up visits at home
Previously not enrolled in pregnant and lactating women trials
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allocation are blinded. Baseline information regarding nutrition and exclusive breastfeeding will be recorded. Anthropometric measurements of both the mother and
newborn will be performed, and follow-up procedures will
be explained. Figure 1 shows the trial processes in detail.
Blinding

The outcome assessors, responsible only for the anthropometry measurements, will be blinded and assigned a
schedule that does not overlap with those of the followup teams. All investigators will also be blinded to group
allocation throughout the period of the study. Moreover,
an interim analysis on the blinded arms will be executed
by an independent statistician for the Data Safety and
Monitoring Board (DSMB). Furthermore, the data analyst performing the final analysis will also be blinded,
and the code will eventually be revealed after the blinded
results will be shared with DSMB and investigators in a
final review meeting.
Interventions

In the control arm, standard of care, i.e., ANC care, nutritional counseling, health promotional messages of exclusive breastfeeding, and care for intrapartum and

Fig. 1 Consort diagram
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postnatal care will be disseminated to all pregnant
women. In “Intervention arm 1,” in addition to the
standard of care, 2 sachets of BEP supplements per day
from enrolment till birth outcome will be allocated to
each woman by a trained research team member at initial and subsequent follow-up visits. BEP is a certified
product of the World Food Program and is locally produced by the Ismail Industries in Karachi. The manufacturers have no role in any part of the study. Each sachet
contains a caloric value of 400 kcal per 75 g and approximately 10.5 g of protein. The sources of protein are
mainly chickpea, peanuts, lentils, legumes, and skimmed
milk. In “Intervention arm 2,” the same standard ANC
counseling BEP interventional doses will be administered
to each participant in addition to 2 prophylactic doses of
azithromycin tablets 2 g orally at weeks 20 and 28 of
gestation (window period of 7 days). In “Intervention
arm 3” lastly, daily single doses of nicotinamide 100 mg
orally and choline 450 mg orally will be dispensed to
each pregnant woman in addition to the same standard
of care plus BEP diet supplements. Provision of all ANC
services as well as referral for any complication(s) during
pregnancy and intrapartum period will be undertaken
for all arms. Provision of all ANC services as well as
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referral for any complication(s) during pregnancy and
intrapartum period will be undertaken for all arms.
There will be no alternation to the usual care pathways
(including use of any medication) and these will continue for all trial arms. All other non-study treatments,
such as medications and supplements, will be recorded
at each follow-up in all arms. In case any severe illness
or adverse event is reported or observed, the intervention may be paused or stopped for a limited period after
the investigators and the Data Safety and Monitoring
Board are consulted.
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collected. After birth outcome assessment, the motherinfant dyad will be followed through 0–11 months of infant’s age on a periodic basis. There is no plan of retention for these participants once their 11-month followups are completed. However, through our existing freeof-cost primary health care facilities, standard-of-care is
available to all participants, even after the completion of
the trial. For participants who move out of the catchment area, a tracking system has been developed so that
they can be followed up at the new location in case it is
in close proximity. Table 2 shows the schedule of enrollment, interventions, and assessments.

Data collection and data management

Case report forms (CRFs) are designed to capture details
on screening, eligibility, randomization, household demography, pregnant assessment, danger signs, severe adverse events, interventional compliance, 24-h food recall
(to estimate usual intake plus diversity on a monthly
basis), and anthropometry. The data will be collected by
a trained team on electronic tablets, with intrinsic logic
checks and skip patterns, and updated on secure servers
in real time using digital applications, which are designed and built in-house. Auto-alerts will be used to remind about each participant’s follow-up as per schedule,
and the data will be tracked according to key indicators.
All the data will be collected in a real-time manner and
uploaded on a cloud server, which is password-protected
and only accessible to the trial data management team
and manager. Participants’ confidentiality will be maintained through a unique ID system, and the participant
identification information will not be exposed to anyone
outside the trial team. The tablets in use will be
password-protected and only accessible to the study
team. De-identified data will be used for analysis
purposes.
Follow-ups

Domestic visits will be paid by the follow-up teams to
provide counseling for all arms. BEP will also be provided to all intervention arms, and compliance will be
measured by logging the number of empty sachets since
the last visit. Azithromycin oral dose (intervention arm
2) will be given to pregnant women by the research team
with close monitoring of adverse events if reported or
observed. Similarly, daily administration of nicotinamide
and choline will also be the responsibility of the designated follow-up team (intervention arm 3). Follow-ups
will be performed daily for the first 15 days following enrollment, every 72 h in the following 2 weeks, and, then
weekly in the next stages of pregnancy till birth outcome. At each visit, counseling will be provided to the
participants to reinforce adherence to the BEP supplementation and other protocol-related procedures. In
addition, monthly 24-h food recall data will also be

Anthropometry

The teams will be trained to perform anthropometric
measurements for each mother-infant dyad using the
INTERGROWTH-21st standards by a master trainer
who will also conduct monthly refreshers. The measurements will include maternal height, mid-upper arm circumference (MUAC), and weight as well as infant
length, weight, MUAC, and head circumference. SECA
infant weighing scale model 334 will be used for infantile
weight measurement whereas the SECA adult weighing
scale model 874 will be used to assess the maternal
weight. MUAC tapes from UNICEF will be imported.
The SECA scale models 417 and 213 will be used to
measure the maternal height and infantile length respectively. The team members recording anthropometric
measurements will be blinded to the allocated arms of
participants. Data will be entered digitally in the system
which will automatically calculate the average value. The
allowable difference between the two study measurements according to the standard procedure is ± 0.5 cm
for maternal MUAC, ± 0.2 kg for maternal weight, ± 0.5
cm for maternal height, ± 20 g for infant weight, and ±
0.4 cm for infant length, infant MUAC, and infant head
circumference.
Primary outcome

The primary outcome of interest will be the birth weight
(g) of the newborn assessed within 72 h of birth.
Secondary outcomes

The other outcomes of interest will be birth length (cm),
head circumference (cm), and MUAC (cm) of the newborn assessed in less than 72 h of birth. For extended
follow-ups on days 3, 6, 21, 27, 42, 59, 89, 114, 143, 179,
269, and 359 from 0 to 11 months after birth, anthropometry of the mother-infant dyad will be assessed.
Weight velocity (g/day), length velocity (cm/month),
length-for-age z-score (LAZ), weight-for-age z-score
(WAZ), and weight-for-length z-score (WLZ) will thereafter be calculated. Weight velocity is defined as the incremental change in weight (in grams) per day from
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Newborn and maternal anthropometry measurements
within 72 h of birth performed by separate team
(blinded from intervention details)

Birth outcome assessment

Maternal stool collection

Maternal plasma collection for Niacin metabolites

Maternal plasma collection for proteomics

Maternal urine collection for Choline metabolites

Maternal VAM blood collection

Maternal vitamin D level

j

Maternal hemoglobin level

Maternal ferritin level

×

×

×

Specimens’ collection during pregnancy

×

×

Participant experience and rating different
characteristics of BEP product g

Week 23, 27, 31,
35, 39 of gestation

Maternal depression

×

×

×

×

×

Weeklyf

Week
19

×

×

×

×

×

×

Daily
visitse

Follow-ups for
maternal
anthropometry

Monthly maternal anthropometry measurements
performed by separate team (blinded from
intervention details)

24 h maternal food intake recall i

×

×

×

×

72 hourly
visits d

×

k

×
×

48 hourly
visits c

Infant assessment for danger sign

×

×

Daily
visitsb

Follow-ups collecting data on key study
variables and indicators

24 h breastfeeding recall

Follow-ups during pregnancy

Oral Azithromycin administration at week 20 and
28 with daily follow-ups for SAEs monitoring after
dose administration h

BEP distribution and compliance assessment

Nutrition counseling and ANC

×

×

Baseline data

g

×

Randomization and allocation

Intervention

×

Written informed consent

T0a

Eligibility assessment

Enrollment

Timepoints

Table 2 Time schedule of enrollment, interventions, and assessments
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k

MRI scan of infants

k

c

b

Window period for eligibility assessment and enrollment is 8–18.9 weeks of gestation
Initial 1–13 days from enrollment
15–25 days from enrollment
d
29–38 days from enrollment
e
Pre- and post-Azithromycin administration, i.e., at weeks 20 and 28 of gestation
f
48 days from enrollment
g
Only in intervention arm
h
Only in intervention arm C and window period of 7 days
i
Only monthly basis
j
All participants who agreed
k
Sub-sample of 50 in each arm

a

72 hourly
visits d

Daily
visitse

Weeklyf
Week 23, 27, 31,
35, 39 of gestation

Week
19

Week
32

×

×

At birth

Primary study
endpoint

×

×

Extended follow-up
Mother-infant dyad
(Secondary study
end points)
1–2 months,
3–4 months,
5–6 months and
12 months

×

48 hourly
visits c

Follow-ups for
maternal
anthropometry

Neurodevelopment assessment using Mullen, HINE
and GSED – at 6 and 12 months of infant’s age plus
maternal depression l

Daily
visitsb

Follow-ups collecting data on key study
variables and indicators

×

T0a

Monthly infant and maternal anthropometry
measurements performed by separate team (blinded
from intervention details)

Infant’s growth and neurodevelopment assessment

Mother-infant dyad stool collection

k

Mother-infant dyad VAM blood collection

Specimens’ collection during extended follow-up

Breast milk collection within 72 h of birth k

Cord blood collection within 30 min of birth

Timepoints

Table 2 Time schedule of enrollment, interventions, and assessments (Continued)
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birth to 11 months of age. Similarly, length velocity is
defined as the progressive change in length (in centimeters) per month measured from birth to 11 months of
infantile age. Moreover, the mean differences in the specific z-score indicators (LAZ, WAZ, and WLZ) measured at birth and 11 months of age will be assessed.
Because anthropometric data for each mother-infant
dyad is available on different periodic days as per their
follow-up schedule, the aforementioned outcomes
assessed according to each follow-up’s duration. Furthermore, the anthropometric measurements of the mother
will also be assessed on a monthly basis during pregnancy, i.e., height (cm) (only at enrollment), weight (kg),
and MUAC (cm), and body mass index (BMI). The
mean change in each of these indicators for different
arms will be assessed during pregnancy and in extended
postnatal follow-ups.
Other secondary outcomes
Neurodevelopment assessment of infants

In order to assess the impact of maternal interventions
on early childhood development (ECD) as growth trajectory, four different approaches or tools will be used to
determine the changes at 6 and 12 months of age. This
will be undertaken by a team of psychologist and trained
senior research staff.
Early learning and motor ability The “Mullen Scales of
Early Learning” will serve as a compass for assessing
cognitive and motor ability of each infant. The scale will
use gross motor, visual reception, fine motor, expressive
language, and receptive language to score target
strengths and weaknesses among the infants, with each
module having specific skip patterns to follow according
to age group. The module for infants less than 12
months of age usually takes 25–35 min to complete.
This examination will be performed on all eligible
infants.
Neurological examination The “Hammersmith Infant
Neurological Examination (HINE)” will be used for the
neurological examination of infants. It consists of six
subscales (tone, tone patterns, reflexes, spontaneous
movements, abnormal neurological signs, and behavior)
and a total score. There are 34 items, with a maximum
possible score of one per item, the points of which are
totaled to provide an overall optimality score, as well as
the six subscale scores. This will be performed on all eligible infants.
Global Scale for Early Development The Global Scale
for Early Development (GSED) aims to fill the neurological and biopsychosocial gap that may present in infancy and childhood through the development of two
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internationally standardized and validated measurement
instruments for the assessment of ECD in children
under 3 years of age at population (short form) and programmatic (long form) levels. The instruments are being
developed by a multidisciplinary team led by the World
Health Organization. Both GSED instruments are constructed from a common item bank (see box for detailed
methodology). The first is a short, caregiver-report instrument intended for population-level measurement to
assess and map child development status, draw attention
to populations in most need of support, track trajectories of child development over time at a population level,
and monitor benefits of national-level policies and programming. The second is a longer instrument for program evaluation that combines direct assessment and
caregiver report to quantify the impact of an intervention
on early developmental outcomes. Both forms are developed to be culturally neutral, easy to administer; openaccess and freely available; acceptable and understandable
to caregivers and children; and easily interpretable by policymakers and program personnel. The instruments are
designed to be holistic measures for interpretation at the
population or group level. They are not intended for individual diagnosis or screening of children. The data collected via GSED will provide the conceptual and empirical
basis for the future development of “norms” that can be
used to monitor the proportion of children who are developmentally on track [31].
Brain morphology On a sub-sample of 50 infants per
arm, brain imaging will be performed using magnetic
resonance imaging (MRI) to assess brain volumes and
morphometry. The portable low-field scanner, “Hyperfine MRI machine” will be used for this purpose. Approved by the Food and Drug Authority (FDA) [32], this
new diagnostic tool will be used to assess brain development in complement to other ECD assessments mentioned above.
Participant experience and rating different characteristics of
BEP product

At weeks 19 and 32 of gestation, the participants in the
intervention arms will be approached to share their
product experience with BEP supplements. This will include product taste, odor, texture, physical appearance,
and packaging.
Maternal depression

Antenatal period Pregnant women will be screened for
depression at weeks 19 and 32 of pregnancy by a team
of one psychologist and trained senior research using
the “Patient Health Questionnaire 9-item tool (PHQ9)”
will be used to screen the. In subject(s) requiring urgent
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care based on the finding, a referral for higher-level care
will be furnished for further diagnosis and treatment.

signing the material transfer agreement (MTA) for additional metagenomic and microbiome analyses.

Post-partum period Using Edinburgh Postnatal Depression Scale (EPDS) tool, data on maternal depression at 6
and 12 months post-partum will be collected by the
same team of one psychologist and trained senior research staff. In a case where participant(s) require urgent
care based on the finding, a referral for higher-level care
will be furnished for further diagnosis and treatment.

Biomarker assessment during pregnancy period

Biomarker assessment during pregnancy period

Breast milk collection Colostrum from the same
women will be collected within 72 h of birth to assess
the quality and composition of breast milk in terms of
macro- and micronutrients, including oligosaccharides,
immunoglobulins, and microbiome. The analysis of
breast milk specimens will be performed in the Azad
Lab at the University of Manitoba. A material transfer
agreement (MTA) will be developed with the University
of Manitoba for the shipment of the specimens.

Maternal blood specimen collection Maternal blood
will be collected at enrollment and 32 weeks of pregnancy from all consensual participants to assess the
levels and differences of hemoglobin (g/dl), ferritin (ng/
ml), and vitamin D (ng/ml) from each arm. Separate
blood specimens for metabolomic analyses will be simultaneously drawn using the “Volumetric Absorptive
Microsampling” (VAM) technique.
On a sub-sample of 50 pregnant women per arm
approached via convenience sampling, plasma for Niacin
metabolites and for niacin co-enzymes, specifically
erythrocyte nicotinamide adenine dinucleotide (NAD)
and nicotinamide adenine dinucleotide phosphate
(NADP), will also be collected at the same time point to
compare the levels of these metabolites among the four
arms with those receiving an extra daily dose. On this
same sub-sample, plasma for proteomic analysis will be
collected at 19 and 32 weeks of pregnancy to gain an indepth analysis of proteome and assess the potential impact of administrating azithromycin.
Maternal urine specimen collection Urine sample will
be collected from the same sub-sample as above at enrollment and 32 weeks of pregnancy to see how the level
of choline metabolites differ in the four arms compared
to the one receiving an extra daily dose of choline.
Maternal stool specimen collection Stool specimen on
the same sub-sample of 50 pregnant women per arm will
also be collected at 19 and 32 weeks of pregnancy. The
specimens will be assessed for inflammatory biomarkers
in the stool, such as calprotectin (μg/g), lipokalin-2 (pg/
ml), and myeloperoxidase (MPO), using ELISA. Furthermore, the stool samples will also be analyzed for enteropathogens using the TaqMan Array Card (TAC) system
for polymerase chain reaction (PCR), which will be performed in the Infectious Disease Research Lab (IDRL).
Moreover, a targeted Bifidobacterium identification will
be performed using real-time PCR at IDRL. The stool
samples will be sent to the University of Stanford after

Cord blood collection On the group of the same subsample as above, cord blood will be collected within 30
min of birth using dried blood spot (DBS) cards to assess
micro- and macronutrients and antibody status in the
cord blood.

Maternal and infant stool specimen collection Stool
specimen on the same sub-sample of 50 mother-infant
dyad per arm will also be collected at 1–2, 3–4, 5–6, and
12 months of infantile age. Specimens will be assessed
for inflammatory biomarkers in the stool, such as calprotectin (μg/g), lipokalin-2 (pg/ml), and myeloperoxidase
(MPO), using ELISA. Furthermore, the stool samples
will also be analyzed for enteropathogens using the TaqMan Array Card (TAC) system for PCR, which will be
performed in the Infectious Disease Research Lab
(IDRL). Moreover, a targeted Bifidobacterium identification will be undertaken using real-time PCR at IDRL.
The stool samples will be sent to the University of Stanford after signing the material transfer agreement
(MTA) for additional metagenomic and microbiome
analyses.
Blood specimen collection From the same 50 motherinfant dyads per arm, infantile blood specimens will also
be simultaneously collected at 1–2, 3–4, 5–6, and 12
months of infantile age for metabolomic work using
Volumetric Absorptive Microsampling (VAM). The
specimens will be stored in − 80 °C freezers at the IDRL
and NRL storage areas of the Aga Khan University for
further analysis in future research for an indefinite time.
The samples will be color-coded by the type of specimen
as part of a unique identification system and deidentified with barcodes, specific IDs for different time
points, and mother-infant dyad information. All the ethical aspects pertaining to the storage of these samples
have been approved by the Ethics Review Committee at
the Aga Khan University.
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Monitoring and quality assurance

or choline doses. Information of all adverse event occurrences at each follow-up will be collected systematically
via exhaustive history-taking for any illness since the past
visit and assessing signs of concern at each visit. If the
pregnant women are considered to have any concerning
sign or symptom, a referral mechanism has been put in
place. A 24/7 active contact number will be provided to
the participants to report any serious illness, for which immediate referral will be arranged. This information will be
well-documented and recorded under the “severe adverse
events” field. For reporting to the ethics committee and
DSMB, “severe adverse events” has been divided into two
main categories: “fatal events” that may be occurring regardless of the underlying cause, and “non-fatal events”
that may require hospitalization or injectable therapy during the follow-up period. Risk management includes prevention through rigorous follow-ups, and continuous
monitoring, documentation, and prompt referrals for danger signs. Every illness or danger sign reported or identified is addressed through facilitated referral for both
women and infants.

A specific team from the Aga Khan University, with expertise in data management and trial implementation
working with the investigators, will be responsible for
auditing the general data trial processes and training the
research staff and outcome assessors to ensure the completeness and accuracy of the protocols. Moreover, the
Technical Advisory Group (TAG) comprising of international experts will be evaluating the trial progress and
independent experts will visit the catchment periodically
for monitoring. A mechanism has also been developed
for the research teams to report key progress indicators
on a weekly basis to the investigators at the VITAL
Pakistan Trust and Aga Khan University. Furthermore,
an astringent quality assurance mechanism has been developed through which 10% of randomly selected data
will be checked by trial supervisors and associates. The
anthropometric measurements will be standardized, and
the team members will be trained by WHO-trained master trainers. Comprehensive training and refreshers will
be conducted on a routine basis for the research team
members, all of whom have received Good Clinical Practice certifications.
Data safety and monitoring board

The independent group of experts, comprising of 5 members, constitutes the Data Safety and Monitoring Board
(DSMB) for the trial and are responsible for monitoring
safety indicators, adverse events, and results of the interim
analysis. The interim analysis (blinded by arm) is scheduled for when 50% of the enrolled participants complete
the 6-month follow-up. Only DSMB members will have
access to the results of interim analysis, which will be
shared by the independent statistician. Data on severe adverse events will be shared with the board on a monthly
basis in the form of a progress report.
Participant safety

Close follow-up will be performed to ensure participant
safety, and pregnant women will be referred to physicians
at the primary health care clinic if needed, with facilitated
referral to tertiary hospitals when required. An independent DSMB will monitor the safety of the study participants
and practice trial oversight. Monthly reports on severe adverse events will be shared with DSMB, and when a safety
red signal is observed, DSMB may stop this trial prior to
the completion of recruitment. The safety net, including
facilitated referral and reporting, is believed to minimize
the chances of harm to participants.
Possible risks

Trial participants may experience diarrhea, nausea, vomiting, skin rash, and abdominal distension after BEP supplementation and/or following azithromycin, nicotinamide,

Statistical analysis

All analyses will be done using Stata software version 16.
Descriptive analysis of each group will be conducted,
and percentages or continuous data with SD will be reported. The baseline characteristics will be assessed by
arm. The primary approach will be intention-to-treat
(ITT) analysis to compare primary and secondary
growth outcomes. Mean differences will be assessed
using one-way ANOVA, with the model adjusted for
baseline characteristics including maternal age, BMI,
gestational age, gravidity, MUAC, and newborn age at
birth assessment. Key assumptions are that outcome
data will be repeatedly measured, normally distributed,
and following the superiority principle. For covariate
analysis, both the unadjusted and stepwise-adjusted
models will be run. Point estimates less than 10% will be
reported as unadjusted despite of the model employed.
Potential sub-group analyses for primary and secondary
outcomes will be based on infantile gender and maternal
data at enrolment, i.e., MUAC < 21.0 cm or ≥ 21.0 cm,
age < 30 years or ≥ 30 years, gravidity < 3 or ≥ 3, and
BMI < 18.5 kg/m2 or ≥ 18.5 kg/m2.
Participants and public involvement

The investigators have extensive experience working
with the community and their representatives/elders.
During the protocol development phase, the team discussed and received feedback on the research question
and trial design from the community representatives.
Furthermore, community perspectives about the trial
procedures, especially the frequency and duration of
follow-up and biospecimen collection procedure, were
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also considered. Additionally, during the pilot phase, the
aim was not only to test the consent form and questionnaires but also to understand the community response
to different questions and how sensitive information regarding the antenatal and postnatal periods can be collected in a receptive and profound manner.
Ancillary care

VPT will pay for ancillary care in case the participants
incur any harm owing to trial participation or have
health issues not monetarily covered by the national
healthcare program.
Confidentiality

During the trial, the data files containing personal identifying information will be stored in a password-secured
server. Only the members in the top hierarchy of the research team, i.e., principal investigator and project coordinators, will have access to those files. Moreover,
biological samples collected from the field site will be
de-identified to respect the privacy of study participants.
Dissemination plan

Processes will be developed to facilitate collaborative
data-sharing for scientific purposes. De-identified data
with analytical/statistical codes will be made available to
the public domain 2 years after the publication of the
principal manuscripts. However, investigator support
will be needed for which the approval of the proposal
and counter-signatures of the data access agreement are
a requisite. The data will be uploaded on a passwordsecured cloud server at all times.

Discussion
This paper describes the protocol of an open-label, randomized controlled trial in the Rerhi Goth slum. The
control and intervention groups will both receive standard ANC counseling. Additionally, PW will receive a
BEP supplement coupled with prophylactic antibiotics or
micronutrients in the intervention group. This study will
thus allow us to assess neonatal anthropometric velocity
through improved maternal nutrition. The salient features of the present trial are the co-administration with
azithromycin or choline and nicotinamide with BEP supplements for comprehensive learning of nutritional supplement efficacy in the study population. The administration
of these supplements at particular lapses of pregnancy will
enable us to assess the specific titer of prenatal supplementation needed to yield optimal perinatal outcomes. Close
surveillance of daily supplementation will ensure compliance and prevent misutilization of the interventional
products.
VPT has already preceded several similar trials in the
study setting in the past. This promises a better
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hindsight of the issues that arose in the previous trials
and alleviate them for the upcoming studies. For instance, pregnant women who had stable jobs were usually non-compliant to the doses dispensed. This posed
problems with supplementation compliance in the past
and was considered during the current trial, thus leading
to their exclusion from participation in this study. Multiple sub-studies nested in the main trial can provide
insight into the mechanism by which prenatal BEP supplementation affects perinatal outcomes. And last, similar studies are being conducted in other developing
countries, allowing for comparison of results from different contexts.
The Mumta PW trial will thus cite the impact of BEP
supplements on neonatal and infantile anthropometric
outcomes using a rigorous study design. The study results
will further strengthen and refine the WHO’s recommendation on using context-specific BEP supplementation
during pregnancy for impoverished settings.
Strengths and limitations of this study

The study was uniquely designed from the perspective
that robust data on nutritional interventions are grossly
lacking for pregnant women in resource-impoverished
settings, let alone the impact of such interventions combined with a prophylactic dose of azithromycin or nicotinamide and choline. Potential biases which could have
imposed foreseeable limitations on the trial results are
enlisted below. The respective countermeasures undertaken to eliminate these biases are also mentioned.
1. Selection bias: This may have occurred due to the
unblinded nature of the study and has been
mitigated by independent allocation-sequencing and
block randomization.
2. Performance bias and detection bias: The blinding
of the outcome assessors to the study arms through
independent teams will decrease this bias.
3. Incomplete outcome data (attrition bias): The
period of follow-up throughout pregnancy and beyond to 12 months of infantile age, is substantially
long and leads to a risk of participants being lost to
follow-up. However, efforts will be made to mitigate
this through communication with the community
in the trial run-in period and connecting with families. If a participant moves away from the catchment area, they will be followed at their new
address until the outcome of the trial if possible.
Regardless, all available data will be used during
analysis, even if there is missing data at certain time
points.
4. Non-compliance bias: Non-compliance can be
caused by the taste and potential adverse effects of
the supplements and long duration of consumption.
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Table 3 Protocol versions
Version

Date and changes

1.0

May 21, 2018—Original protocol

1.1

June 16, 2018—Proposed dose azithromycin as 1 g at weeks 20 and 28 of gestation

1.2

August 24, 2018—Proposed dose azithromycin as 2 g at weeks 20 and 28 of gestation

1.3

January 26, 2019—Addition of fourth arm

1.4

August 15, 2020—Addition of secondary outcomes like specimens, extended follow-ups, and neurodevelopment assessment

1.5

April 12, 2021—Increase in sample size based on new dropout rates due to C0VID-19 pandemic impact of health services

1.6

October 9, 2021—Recalculation of sample size based on TAG recommendations for multiple arm comparison

This will be addressed through detailed counseling
at the time of consent and sufficient time provision
to potential study participants for decision-making
and/or seeking the input of the household decisionmakers. Continuous counseling at each follow-up
throughout all arms is also the key to prevent
dropouts.
5. Contamination: This will be prevented by enrolling
only one participant from a single household and
through the provision of excess supplements, as
women are likely to feed the supplements to other
members of the family.
Trial status

Active protocol version number: 1.6, October 9, 2021.
Protocol amendments have been submitted, and the details of the protocol versions with the date of the amendment are provided in Table 3. Started on 22nd July
2019, the recruitment is currently ongoing and is expected to be completed in January 2022, while the last
follow-up is expected to be completed in December
2023. The database will be locked in June 2024.
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